Program
SAL-0951
A development code. Also written as “SAL-0951 tablets”, “SAL-0951 tablets 4mg” and “SAL-0951 tablets 5mg”.
Its studies are mostly in Anemia, led by Shenzhen Salubris Pharmaceuticals.
Furthest: phase 3, since Aug 23, 20234 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 41 open or running | phase 3since Aug 23, 2023 | Aug 23, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2023First study: phase 3 study in Renal Anemia in Non-dialysis Chronic Kidney DiseaseFirst studyNCT06016036 · 156 enrolled · China
- Dec 2, 20242 phase 3 studies in AnemiaNCT06720233, NCT06720025
- Dec 4, 2024Phase 2 study in AnemiaNCT06737081 · 60 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06737081Anemia · China | 2 | Recruiting | Dec 31, 2025 | 60 |
| NCT06720233Anemia · China | 3 | Completed | Oct 18, 2024 | 37 |
| NCT06720025Anemia · China | 3 | Completed | Jun 17, 2024 | 100 |
| NCT06016036Renal Anemia in Non-dialysis Chronic Kidney Disease · China | 3 | Completed | Oct 8, 2021 | 156 |
How it is read
Names in the registry
- “SAL-0951 tablets”, 2 entries
- “SAL-0951 tablets 4mg”, 1 entry
- “SAL-0951 tablets 5mg”, 1 entry
- “SAL-0951”, 1 entry
Codes read as this program: SAL0951.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.